Legal Representation
Attorney
Nicole Kinsley, Esq.
USPTO Deadlines
Next Deadline
44 days remaining
Abandonment Notice E-Mailed - No Use Statement Filed
Due Date
August 30, 2025
Application History
39 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 30, 2025 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Jun 30, 2025 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Nov 26, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Oct 1, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Oct 1, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Sep 11, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Aug 28, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Apr 4, 2024 | PCGR | O | PETITION TO DIRECTOR GRANTED | Loading... |
| Apr 1, 2024 | APET | A | ASSIGNED TO PETITION STAFF | Loading... |
| Feb 29, 2024 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | Loading... |
| Feb 29, 2024 | GNSL | S | LETTER OF SUSPENSION E-MAILED | Loading... |
| Feb 29, 2024 | CNSL | R | SUSPENSION LETTER WRITTEN | Loading... |
| Feb 22, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Feb 22, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Feb 22, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Nov 27, 2023 | TPDR | I | TEAS PETITION TO DIRECTOR RECEIVED | Loading... |
| Nov 24, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Nov 24, 2023 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Nov 24, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Nov 23, 2023 | ZZZX | Z | PREVIOUS ALLOWANCE COUNT WITHDRAWN | Loading... |
| Oct 17, 2023 | PBCR | Z | WITHDRAWN FROM PUB - OG REVIEW QUERY | Loading... |
| Sep 29, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Sep 27, 2023 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Sep 27, 2023 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Sep 27, 2023 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Sep 27, 2023 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Aug 18, 2023 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | Loading... |
| Aug 18, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Aug 18, 2023 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Aug 18, 2023 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Jun 14, 2023 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| Jun 14, 2023 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Apr 19, 2023 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Mar 14, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Mar 14, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Mar 14, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Mar 13, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| May 31, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| May 27, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for human use, namely, pharmaceuticals for the treatment of cancer, metabolic diseases, cardiovascular diseases, neurological diseases, age-related diseases, immunological diseases, and genetic diseases, pharmaceuticals for the treatment of diseases and disorders with genetic etiology, gene therapies, and nucleic acid therapies; house mark for pharmaceutical preparations for human use, namely, pharmaceuticals for the treatment of cancer, metabolic diseases, cardiovascular diseases, neurological diseases, age-related diseases, immunological diseases, and genetic diseases, pharmaceuticals for the treatment of diseases and disorders with genetic etiology, gene therapies, and nucleic acid therapies; pharmaceutical preparations for veterinary use, namely, pharmaceuticals for the treatment of cancer; house mark for pharmaceutical preparations for veterinary use, namely, pharmaceuticals for the treatment of cancer and age-related disease; cosmeceuticals, namely, medicated skin and hair care preparations; house mark for cosmeceuticals, namely, medicated skin and hair care preparations
Classification
International Classes
005